View in EDS HTML Full Text PDF Full Text

Characterisation of SARS-CoV-2 genomic variation in response to molnupiravir treatment in the AGILE Phase IIa clinical trial.

Saved in:
Bibliographic Details
Title: Characterisation of SARS-CoV-2 genomic variation in response to molnupiravir treatment in the AGILE Phase IIa clinical trial.
Authors: Donovan-Banfield I; Department of Infection Biology and Microbiomes, Institute of Infection, Veterinary and Ecological Sciences, University of Liverpool, Liverpool, UK.; NIHR Health Protection Research Unit in Emerging and Zoonotic Infections, Liverpool, UK., Penrice-Randal R; Department of Infection Biology and Microbiomes, Institute of Infection, Veterinary and Ecological Sciences, University of Liverpool, Liverpool, UK., Goldswain H; Department of Infection Biology and Microbiomes, Institute of Infection, Veterinary and Ecological Sciences, University of Liverpool, Liverpool, UK., Rzeszutek AM; Department of Evolution, Ecology and Behaviour, Institute of Infection, Veterinary and Ecological Sciences, University of Liverpool, Liverpool, UK., Pilgrim J; Department of Evolution, Ecology and Behaviour, Institute of Infection, Veterinary and Ecological Sciences, University of Liverpool, Liverpool, UK., Bullock K; GCPLab Facility, Institute of Systems, Molecular and Integrative Biology, University of Liverpool, Liverpool, UK., Saunders G; Southampton Clinical Trials Unit, University of Southampton, Southampton, UK., Northey J; Southampton Clinical Trials Unit, University of Southampton, Southampton, UK., Dong X; Department of Infection Biology and Microbiomes, Institute of Infection, Veterinary and Ecological Sciences, University of Liverpool, Liverpool, UK., Ryan Y; Department of Infection Biology and Microbiomes, Institute of Infection, Veterinary and Ecological Sciences, University of Liverpool, Liverpool, UK., Reynolds H; Department of Pharmacology and Therapeutics, Institute of Systems, Molecular and Integrative Biology, University of Liverpool, Liverpool, UK., Tetlow M; Department of Pharmacology and Therapeutics, Institute of Systems, Molecular and Integrative Biology, University of Liverpool, Liverpool, UK., Walker LE; Department of Pharmacology and Therapeutics, Institute of Systems, Molecular and Integrative Biology, University of Liverpool, Liverpool, UK.; NIHR Royal Liverpool and Broadgreen Clinical Research Facility, Liverpool University Hospitals NHS Foundation Trust, Liverpool, UK., FitzGerald R; Department of Pharmacology and Therapeutics, Institute of Systems, Molecular and Integrative Biology, University of Liverpool, Liverpool, UK.; NIHR Royal Liverpool and Broadgreen Clinical Research Facility, Liverpool University Hospitals NHS Foundation Trust, Liverpool, UK., Hale C; NIHR Royal Liverpool and Broadgreen Clinical Research Facility, Liverpool University Hospitals NHS Foundation Trust, Liverpool, UK., Lyon R; NIHR Royal Liverpool and Broadgreen Clinical Research Facility, Liverpool University Hospitals NHS Foundation Trust, Liverpool, UK., Woods C; NIHR Royal Liverpool and Broadgreen Clinical Research Facility, Liverpool University Hospitals NHS Foundation Trust, Liverpool, UK., Ahmad S; NIHR Manchester Clinical Research Facility, Manchester University NHS Foundation Trust, Manchester, UK., Hadjiyiannakis D; NIHR Lancashire Clinical Research Facility, Lancashire Teaching Hospitals NHS Foundation Trust, Preston, UK., Periselneris J; NIHR Kings Clinical Research Facility, King's College Hospital NHS Foundation Trust, London, UK., Knox E; Southampton Clinical Trials Unit, University of Southampton, Southampton, UK., Middleton C; Southampton Clinical Trials Unit, University of Southampton, Southampton, UK., Lavelle-Langham L; GCPLab Facility, Institute of Systems, Molecular and Integrative Biology, University of Liverpool, Liverpool, UK., Shaw V; GCPLab Facility, Institute of Systems, Molecular and Integrative Biology, University of Liverpool, Liverpool, UK.; The Clinical Directorate, University of Liverpool, Liverpool, UK., Greenhalf W; GCPLab Facility, Institute of Systems, Molecular and Integrative Biology, University of Liverpool, Liverpool, UK., Edwards T; Centre for Drugs and Diagnostics, Liverpool School of Tropical Medicine, Liverpool, UK., Lalloo DG; Liverpool School of Tropical Medicine, Liverpool, UK., Edwards CJ; Human Development and Health School, University of Southampton, Southampton, UK.; NIHR Southampton Clinical Research Facility, University Hospital Southampton NHS Foundation Trust, Southampton, UK., Darby AC; Department of Infection Biology and Microbiomes, Institute of Infection, Veterinary and Ecological Sciences, University of Liverpool, Liverpool, UK.; NIHR Health Protection Research Unit in Gastrointestinal Infections, Liverpool, UK., Carroll MW; NIHR Health Protection Research Unit in Emerging and Zoonotic Infections, Liverpool, UK.; Wellcome Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford, UK., Griffiths G; Southampton Clinical Trials Unit, University of Southampton, Southampton, UK., Khoo SH; Department of Pharmacology and Therapeutics, Institute of Systems, Molecular and Integrative Biology, University of Liverpool, Liverpool, UK., Hiscox JA; Department of Infection Biology and Microbiomes, Institute of Infection, Veterinary and Ecological Sciences, University of Liverpool, Liverpool, UK. julian.hiscox@liverpool.ac.uk.; NIHR Health Protection Research Unit in Emerging and Zoonotic Infections, Liverpool, UK. julian.hiscox@liverpool.ac.uk.; A*STAR Infectious Diseases Laboratories (A*STAR ID Labs), Agency for Science, Technology and Research (A*STAR), Singapore, Singapore. julian.hiscox@liverpool.ac.uk., Fletcher T; NIHR Health Protection Research Unit in Emerging and Zoonotic Infections, Liverpool, UK. Tom.Fletcher@lstmed.ac.uk.; Centre for Drugs and Diagnostics, Liverpool School of Tropical Medicine, Liverpool, UK. Tom.Fletcher@lstmed.ac.uk.
Source: Nature communications [Nat Commun] 2022 Nov 26; Vol. 13 (1), pp. 7284. Date of Electronic Publication: 2022 Nov 26.
Publication Type: Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
Journal Info: Publisher: Nature Pub. Group Country of Publication: England NLM ID: 101528555 Publication Model: Electronic Cited Medium: Internet ISSN: 2041-1723 (Electronic) Linking ISSN: 20411723 NLM ISO Abbreviation: Nat Commun Subsets: MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
Description
ISSN:2041-1723
DOI:10.1038/s41467-022-34839-9